Together, our demonstrates of the role of MYC in platinum resistant SCLC, the ability of fimepinostat to reduce MYC expression and to have single agent efficacy independent of MYC expression suggests that fimepinostat will be an effective drug for the treatment of SCLC through multiple mechanisms. The gene discussed is MYC; the disease is small cell lung carcinoma.